Vasomera

Vasomera is a stable long-acting vasoactive intestinal peptide (VIP) agonist. Vasomera acts on the G-protein-coupled VPAC2-receptors. Vasomera can be used for the research of cardiomyopathy associated with dystrophinopathies[1].

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Others >> Others

Vasomera (i.v.; 7.5 μg/kg/min; single) improves arterial elastance and ventriculo-arterial coupling and improves indices of diastolic function (i.e., lusitropy) in animals with chronic renoprival hypertension mimicking heart failure with preserved ejection fraction (HFpEF)[1]. Animal Model: Rats[1] Dosage: 7.5 μg/kg Administration: IV, 7.5 μg/kg/min, single Result: Decreased the estimated arterial elastance, improved ventriculo-arterial coupling, reduced filling pressures, accelerated the time-constant of relaxation and improved compliance.

[1]. Carlos L del Rio, et al. Vasomera, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist, Improves Arterial Elastance and Ventriculo-Arterial Coupling in Rats with Induced Diastolic Dysfunction via Renoprival Hypertension. HypertensionVol. 64, No. suppl_1.